A novel peptide interferes with Mycobacterium tuberculosis virulence and survival

Sachin Kumar Samuchiwal; Sultan Tousif; Dhiraj Kumar Singh; Arun Kumar; Anamika Ghosh; Kuhulika Bhalla; Prem Prakash; Sushil Kumar; Ashish Chandra Trivedi; Maitree Bhattacharyya; Gobardhan Das; Anand Ranganathan

doi:10.1016/j.fob.2014.08.001

A novel peptide interferes with Mycobacterium tuberculosis virulence and survival

Sachin Kumar Samuchiwal, Sultan Tousif, Dhiraj Kumar Singh, Arun Kumar, Anamika Ghosh, Kuhulika Bhalla, Prem Prakash, Sushil Kumar, Ashish Chandra Trivedi, Maitree Bhattacharyya, Gobardhan Das, Anand Ranganathan

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Tuberculosis (TB) is a huge global burden, with new and resistant strains emerging at an alarming rate, necessitating an urgent need for a new class of drug candidates. Here, we report that SL3, a novel 33-amino acid peptide, causes debilitating effects on mycobacterial morphology. Treatment with SL3 drastically inhibits the growth of Mycobacterium tuberculosis in vitro as well as in a pre-clinical mouse model for M.tb infection. Microarray analysis of SL3-expressing strain demonstrates wide-scale transcriptional disruption in M.tb. We therefore believe that SL3 and similar peptides may herald a new approach towards discovering new molecules for TB therapy.

Original language	English (US)
Pages (from-to)	735-740
Number of pages	6
Journal	FEBS Open Bio
Volume	4
DOIs	https://doi.org/10.1016/j.fob.2014.08.001
State	Published - Nov 2014

Keywords

Antimycobacterial peptides
ESAT6
Mycobacterium tuberculosis
Protein-protein interaction

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.fob.2014.08.001

Cite this

@article{49ece8dccd61469d9d63e73bf4686da9,

title = "A novel peptide interferes with Mycobacterium tuberculosis virulence and survival",

abstract = "Tuberculosis (TB) is a huge global burden, with new and resistant strains emerging at an alarming rate, necessitating an urgent need for a new class of drug candidates. Here, we report that SL3, a novel 33-amino acid peptide, causes debilitating effects on mycobacterial morphology. Treatment with SL3 drastically inhibits the growth of Mycobacterium tuberculosis in vitro as well as in a pre-clinical mouse model for M.tb infection. Microarray analysis of SL3-expressing strain demonstrates wide-scale transcriptional disruption in M.tb. We therefore believe that SL3 and similar peptides may herald a new approach towards discovering new molecules for TB therapy.",

keywords = "Antimycobacterial peptides, ESAT6, Mycobacterium tuberculosis, Protein-protein interaction",

author = "Samuchiwal, {Sachin Kumar} and Sultan Tousif and Singh, {Dhiraj Kumar} and Arun Kumar and Anamika Ghosh and Kuhulika Bhalla and Prem Prakash and Sushil Kumar and Trivedi, {Ashish Chandra} and Maitree Bhattacharyya and Gobardhan Das and Anand Ranganathan",

year = "2014",

month = nov,

doi = "10.1016/j.fob.2014.08.001",

language = "English (US)",

volume = "4",

pages = "735--740",

journal = "FEBS Open Bio",

issn = "2211-5463",

publisher = "Wiley",

}

TY - JOUR

T1 - A novel peptide interferes with Mycobacterium tuberculosis virulence and survival

AU - Samuchiwal, Sachin Kumar

AU - Tousif, Sultan

AU - Singh, Dhiraj Kumar

AU - Kumar, Arun

AU - Ghosh, Anamika

AU - Bhalla, Kuhulika

AU - Prakash, Prem

AU - Kumar, Sushil

AU - Trivedi, Ashish Chandra

AU - Bhattacharyya, Maitree

AU - Das, Gobardhan

AU - Ranganathan, Anand

PY - 2014/11

Y1 - 2014/11

N2 - Tuberculosis (TB) is a huge global burden, with new and resistant strains emerging at an alarming rate, necessitating an urgent need for a new class of drug candidates. Here, we report that SL3, a novel 33-amino acid peptide, causes debilitating effects on mycobacterial morphology. Treatment with SL3 drastically inhibits the growth of Mycobacterium tuberculosis in vitro as well as in a pre-clinical mouse model for M.tb infection. Microarray analysis of SL3-expressing strain demonstrates wide-scale transcriptional disruption in M.tb. We therefore believe that SL3 and similar peptides may herald a new approach towards discovering new molecules for TB therapy.

AB - Tuberculosis (TB) is a huge global burden, with new and resistant strains emerging at an alarming rate, necessitating an urgent need for a new class of drug candidates. Here, we report that SL3, a novel 33-amino acid peptide, causes debilitating effects on mycobacterial morphology. Treatment with SL3 drastically inhibits the growth of Mycobacterium tuberculosis in vitro as well as in a pre-clinical mouse model for M.tb infection. Microarray analysis of SL3-expressing strain demonstrates wide-scale transcriptional disruption in M.tb. We therefore believe that SL3 and similar peptides may herald a new approach towards discovering new molecules for TB therapy.

KW - Antimycobacterial peptides

KW - ESAT6

KW - Mycobacterium tuberculosis

KW - Protein-protein interaction

UR - http://www.scopus.com/inward/record.url?scp=84907092904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907092904&partnerID=8YFLogxK

U2 - 10.1016/j.fob.2014.08.001

DO - 10.1016/j.fob.2014.08.001

M3 - Article

AN - SCOPUS:84907092904

SN - 2211-5463

VL - 4

SP - 735

EP - 740

JO - FEBS Open Bio

JF - FEBS Open Bio

ER -

A novel peptide interferes with Mycobacterium tuberculosis virulence and survival

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this